KR101841866B1 - N-[(3-아미노옥세탄-3-일)메틸]-2-(1,1-디옥소-3,5-디하이드로-1,4-벤조티아제핀-4-일)-6-메틸-퀴나졸린-4-아민의 제조 방법 - Google Patents
N-[(3-아미노옥세탄-3-일)메틸]-2-(1,1-디옥소-3,5-디하이드로-1,4-벤조티아제핀-4-일)-6-메틸-퀴나졸린-4-아민의 제조 방법 Download PDFInfo
- Publication number
- KR101841866B1 KR101841866B1 KR1020167020106A KR20167020106A KR101841866B1 KR 101841866 B1 KR101841866 B1 KR 101841866B1 KR 1020167020106 A KR1020167020106 A KR 1020167020106A KR 20167020106 A KR20167020106 A KR 20167020106A KR 101841866 B1 KR101841866 B1 KR 101841866B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- acid
- compound
- temperature range
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *OC(NC1(CN)COC1)=O Chemical compound *OC(NC1(CN)COC1)=O 0.000 description 1
- SEUDVXPZTLKDKT-UHFFFAOYSA-N CC(C)(C)OC(NC1(CBr)COC1)=O Chemical compound CC(C)(C)OC(NC1(CBr)COC1)=O SEUDVXPZTLKDKT-UHFFFAOYSA-N 0.000 description 1
- STTUTVYCMUOETH-UHFFFAOYSA-N CC(C)(C)OC(NC1(CN)COC1)=O Chemical compound CC(C)(C)OC(NC1(CN)COC1)=O STTUTVYCMUOETH-UHFFFAOYSA-N 0.000 description 1
- XACUSKDACTYIST-UHFFFAOYSA-N Cc(cc12)ccc1nc(N(CC1)Cc(cccc3)c3S1=O)nc2NCC1(COC1)N Chemical compound Cc(cc12)ccc1nc(N(CC1)Cc(cccc3)c3S1=O)nc2NCC1(COC1)N XACUSKDACTYIST-UHFFFAOYSA-N 0.000 description 1
- BPGGWEZKGGFKTB-UHFFFAOYSA-N OC(C1(CBr)COC1)=O Chemical compound OC(C1(CBr)COC1)=O BPGGWEZKGGFKTB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/06—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D305/04—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D305/08—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epoxy Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2014/071331 | 2014-01-24 | ||
| CNPCT/CN2014/071331 | 2014-01-24 | ||
| PCT/EP2015/051066 WO2015110446A1 (en) | 2014-01-24 | 2015-01-21 | Process for the preparation of n-[(3-aminooxetan-3-yl)methyl]-2-(1,1-dioxo-3,5-dihydro-1,4-benzothiazepin-4-yl)-6-methyl-quinazolin-4-amine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160102055A KR20160102055A (ko) | 2016-08-26 |
| KR101841866B1 true KR101841866B1 (ko) | 2018-03-23 |
Family
ID=52358790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167020106A Active KR101841866B1 (ko) | 2014-01-24 | 2015-01-21 | N-[(3-아미노옥세탄-3-일)메틸]-2-(1,1-디옥소-3,5-디하이드로-1,4-벤조티아제핀-4-일)-6-메틸-퀴나졸린-4-아민의 제조 방법 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10005770B2 (enExample) |
| EP (2) | EP3097098B1 (enExample) |
| JP (1) | JP6397501B2 (enExample) |
| KR (1) | KR101841866B1 (enExample) |
| CN (2) | CN106414436B (enExample) |
| AR (2) | AR099134A1 (enExample) |
| AU (1) | AU2015208244B2 (enExample) |
| BR (1) | BR112016016978B1 (enExample) |
| CA (1) | CA2934225C (enExample) |
| ES (2) | ES2789798T3 (enExample) |
| HR (2) | HRP20200715T1 (enExample) |
| IL (1) | IL245882B (enExample) |
| MX (1) | MX368110B (enExample) |
| MY (1) | MY176210A (enExample) |
| NZ (1) | NZ721534A (enExample) |
| PL (2) | PL3097098T3 (enExample) |
| RU (1) | RU2664643C2 (enExample) |
| SG (1) | SG11201605916QA (enExample) |
| SI (2) | SI3248969T1 (enExample) |
| WO (1) | WO2015110446A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6749343B2 (ja) | 2015-05-20 | 2020-09-02 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 脊髄性筋萎縮症を処置するための化合物 |
| EP3322704B1 (en) * | 2015-07-16 | 2019-11-27 | H. Hoffnabb-La Roche Ag | Crystalline form of n-[(3-amino-3-oxetanyl)methyl]-2-(2,3-dihydro-1,1-dioxido-1,4-benzothiazepin-4(5h)-yl)-6-methyl-4-quinazolinamine for the treatment of respiratory syncytial virus (rsv) infections |
| NZ739226A (en) | 2015-07-22 | 2022-11-25 | Enanta Pharm Inc | Benzodiazepine derivatives as rsv inhibitors |
| CN108289959B (zh) | 2015-11-12 | 2021-07-16 | 豪夫迈·罗氏有限公司 | 用于治疗脊髓性肌萎缩的组合物 |
| EA201800367A1 (ru) | 2015-12-10 | 2019-02-28 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Способы лечения болезни хантингтона |
| EP3386978B1 (en) | 2015-12-10 | 2021-01-27 | H. Hoffnabb-La Roche Ag | Bridged piperidine derivatives |
| CN108017599B (zh) * | 2016-11-04 | 2020-03-03 | 上海爱科百发生物医药技术有限公司 | [3-(胺甲基)-氧杂环丁烷-3-基]氨基甲酸对甲氧基苄酯对氯苯甲酸盐合成方法 |
| KR20200033249A (ko) | 2017-06-05 | 2020-03-27 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
| US11395822B2 (en) | 2017-06-28 | 2022-07-26 | Ptc Therapeutics, Inc. | Methods for treating Huntington's disease |
| CA3067591A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
| WO2019006295A1 (en) | 2017-06-30 | 2019-01-03 | Enanta Pharmaceuticals, Inc. | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS |
| BR112020006334A2 (pt) | 2017-09-29 | 2020-09-24 | Enanta Pharmaceuticals, Inc. | combinação de agentes farmacêuticos como inibidores de rsv |
| US12103926B2 (en) | 2018-03-27 | 2024-10-01 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| EA202092899A1 (ru) | 2018-06-27 | 2021-05-14 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | Гетероарильные соединения для лечения болезни гентингтона |
| BR112020026545A2 (pt) | 2018-06-27 | 2021-03-23 | Ptc Therapeutics, Inc. | Compostos heterocíclicos e de heteroarila para o tratamento da doença de huntington |
| EP3814360B8 (en) | 2018-06-27 | 2024-11-06 | PTC Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| US11254664B2 (en) | 2019-03-18 | 2022-02-22 | Enanta Pharmaceuticals, Inc. | Benzodiazepine derivatives as RSV inhibitors |
| US11505558B1 (en) | 2019-10-04 | 2022-11-22 | Enanta Pharmaceuticals, Inc. | Antiviral heterocyclic compounds |
| KR20220101083A (ko) | 2019-10-04 | 2022-07-19 | 이난타 파마슈티칼스, 인코포레이티드 | 항바이러스 헤테로사이클릭 화합물 |
| JP7357157B2 (ja) * | 2019-10-31 | 2023-10-05 | シャンハイ アーク バイオファーマスゥ－ティカル カンパニー リミテッド | 呼吸器合胞体ウイルス融合タンパク質阻害剤組成物及びそれを用いてｒｓｖ感染を治療及び予防する方法 |
| CN113149977A (zh) * | 2020-01-22 | 2021-07-23 | 苏州爱科百发生物医药技术有限公司 | 一类呼吸道合胞病毒抑制剂的合成与用途 |
| UY39032A (es) | 2020-01-24 | 2021-07-30 | Enanta Pharm Inc | Compuestos heterocíclicos como agentes antivirales |
| CN111548325A (zh) * | 2020-05-16 | 2020-08-18 | 西安都创医药科技有限公司 | 一种卤代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用 |
| CN111518055A (zh) * | 2020-05-16 | 2020-08-11 | 西安都创医药科技有限公司 | 一种苯并硫氮杂卓氧化物的制备方法及其制备的产品及其应用 |
| CN111620838A (zh) * | 2020-05-16 | 2020-09-04 | 西安都创医药科技有限公司 | 一种氯代苯并硫氮杂卓化合物的制备方法及其制备的产品及其应用 |
| CN111574475B (zh) * | 2020-06-03 | 2022-09-20 | 西安都创医药科技有限公司 | 卤代苯并硫杂卓氧化物的制备方法及其制备的产品及其应用 |
| US11534439B2 (en) | 2020-07-07 | 2022-12-27 | Enanta Pharmaceuticals, Inc. | Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors |
| US11945824B2 (en) | 2020-10-19 | 2024-04-02 | Enanta Pharmaceuticals, Inc. | Heterocyclic compounds as anti-viral agents |
| JP2024507561A (ja) | 2021-02-26 | 2024-02-20 | エナンタ ファーマシューティカルズ インコーポレイテッド | 抗ウイルス複素環式化合物 |
| AR129003A1 (es) | 2022-04-07 | 2024-07-03 | Enanta Pharm Inc | Compuestos heterocíclicos antivirales |
| WO2023211997A1 (en) | 2022-04-27 | 2023-11-02 | Enanta Pharmaceuticals, Inc. | Antiviral compounds |
| WO2025011580A1 (zh) * | 2023-07-10 | 2025-01-16 | 石药集团中奇制药技术（石家庄）有限公司 | 用于治疗和预防呼吸道合胞病毒感染疾病的化合物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013020993A1 (en) | 2011-08-11 | 2013-02-14 | F. Hoffmann-La Roche Ag | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease |
| WO2013053658A1 (en) | 2011-10-11 | 2013-04-18 | F. Hoffmann-La Roche Ag | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease |
| WO2014184163A1 (en) | 2013-05-14 | 2014-11-20 | F. Hoffmann-La Roche Ag | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1383409A (en) * | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
| SE9901573D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
| JP2006518367A (ja) * | 2003-02-21 | 2006-08-10 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | エキソ−（ｔ−ブチル２Ｒ（＋））−２−アミノ−７−アザビシクロ［２．２．１］ヘプタン−７−カルボキシレート、中間体、およびそれらを製造および単離する方法 |
| ES2290743T3 (es) * | 2003-04-30 | 2008-02-16 | The Institutes For Pharmaceutical Discovery, Llc | Heteroarilos sustituidos como inhibidores de las proteina-tirosina fosfatasas. |
| DE102004045648A1 (de) * | 2004-09-21 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika zur Behandlung von Atemwegserkrankungen |
| JP4899385B2 (ja) * | 2005-09-06 | 2012-03-21 | 宇部興産株式会社 | ３−アミノメチルオキセタン化合物の製法 |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| US9040545B2 (en) | 2010-08-20 | 2015-05-26 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors |
| CN105392787B (zh) * | 2013-05-14 | 2017-11-24 | 豪夫迈·罗氏有限公司 | 用于治疗和预防呼吸道合胞病毒感染的氮杂‑氧代‑吲哚 |
-
2015
- 2015-01-20 AR ARP150100146A patent/AR099134A1/es active IP Right Grant
- 2015-01-21 PL PL15700600T patent/PL3097098T3/pl unknown
- 2015-01-21 EP EP15700600.8A patent/EP3097098B1/en active Active
- 2015-01-21 RU RU2016133187A patent/RU2664643C2/ru active
- 2015-01-21 SI SI201531184T patent/SI3248969T1/sl unknown
- 2015-01-21 MX MX2016009514A patent/MX368110B/es active IP Right Grant
- 2015-01-21 MY MYPI2016702654A patent/MY176210A/en unknown
- 2015-01-21 AU AU2015208244A patent/AU2015208244B2/en active Active
- 2015-01-21 KR KR1020167020106A patent/KR101841866B1/ko active Active
- 2015-01-21 CN CN201580005504.5A patent/CN106414436B/zh active Active
- 2015-01-21 CA CA2934225A patent/CA2934225C/en active Active
- 2015-01-21 SI SI201531193T patent/SI3097098T1/sl unknown
- 2015-01-21 BR BR112016016978-6A patent/BR112016016978B1/pt active IP Right Grant
- 2015-01-21 WO PCT/EP2015/051066 patent/WO2015110446A1/en not_active Ceased
- 2015-01-21 ES ES17176794T patent/ES2789798T3/es active Active
- 2015-01-21 CN CN201910222238.1A patent/CN109879837B/zh active Active
- 2015-01-21 PL PL17176794T patent/PL3248969T3/pl unknown
- 2015-01-21 HR HRP20200715TT patent/HRP20200715T1/hr unknown
- 2015-01-21 NZ NZ721534A patent/NZ721534A/en unknown
- 2015-01-21 EP EP17176794.0A patent/EP3248969B1/en active Active
- 2015-01-21 SG SG11201605916QA patent/SG11201605916QA/en unknown
- 2015-01-21 JP JP2016548177A patent/JP6397501B2/ja active Active
- 2015-01-21 ES ES15700600T patent/ES2788900T3/es active Active
-
2016
- 2016-05-26 IL IL245882A patent/IL245882B/en active IP Right Grant
- 2016-07-21 US US15/216,501 patent/US10005770B2/en active Active
-
2018
- 2018-05-24 US US15/988,570 patent/US10253022B2/en active Active
-
2020
- 2020-03-16 AR ARP200100726A patent/AR118371A2/es unknown
- 2020-04-28 HR HRP20200680TT patent/HRP20200680T1/hr unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013020993A1 (en) | 2011-08-11 | 2013-02-14 | F. Hoffmann-La Roche Ag | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease |
| WO2013053658A1 (en) | 2011-10-11 | 2013-04-18 | F. Hoffmann-La Roche Ag | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease |
| WO2014184163A1 (en) | 2013-05-14 | 2014-11-20 | F. Hoffmann-La Roche Ag | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101841866B1 (ko) | N-[(3-아미노옥세탄-3-일)메틸]-2-(1,1-디옥소-3,5-디하이드로-1,4-벤조티아제핀-4-일)-6-메틸-퀴나졸린-4-아민의 제조 방법 | |
| US6576786B2 (en) | Process for preparing substituted cyclopentane derivatives and novel crystalline structures thereof | |
| CN114728923B (zh) | 用于制备氧杂环丁烷-2-基甲胺的方法和中间体 | |
| JP2025061453A (ja) | １，５－ベンゾチアゼピン化合物を製造するための方法 | |
| JP2023536207A (ja) | フタラジノン誘導体及びその中間体を調製するプロセス | |
| HK1231875A1 (en) | Process for the preparation of compound for prophylaxis and treatment of rsv | |
| US9067868B2 (en) | Chemical process for opening ring compounds | |
| EP3833666A1 (en) | Process and intermediates for the preparation of boc-linagliptin | |
| HK1231875B (zh) | 制备用於预防和治疗rsv的化合物的方法 | |
| WO2018130942A1 (en) | A process for the preparation of phenoxybenzamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0105 | International application |
Patent event date: 20160722 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20160722 Comment text: Request for Examination of Application |
|
| PG1501 | Laying open of application | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20170620 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20171219 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20180319 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20180319 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20211229 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20221221 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240226 Start annual number: 7 End annual number: 7 |